29 Sep 2025 | 3 Mins Read
Singaporean bid rejected by company board at 3x the current price
Flipitmoney
Welcure Drugs rejected Telexcell Trade PTE LTD's management control bid, allowing only secondary share purchases to protect shareholder interests and company independence. The board evaluated a significant investment proposal from an overseas firm, valuing Welcure at 3 times its current price, but rejected the offer for management control.